Statement from Kathryn Wylde, President & CEO of the Partnership for New York City, On New York City Being Designated “Top Performer” by Governor Cuomo’s Regional Economic Development Council

Resource Type: News, Statements

“Governor Cuomo’s NYC Regional Economic Development Council was designated a “top performer” and awarded $80.2 million to help advance its priority projects today. Funds will go to job generating activity and community and workforce development across the five boroughs. The REDC process has transformed the state’s approach to economic development, allowing for transparency and encouraging local input into which projects merit state support.”

CEO of Celmatix, Partnership Fund Portfolio Company, Named Disruptive Founder of the Year

Resource Type: Fund News, Partnership Fund

Dr. Piraye Yurttas Beim, Founder and CEO, Celmatix has been named Disruptive Founder of the Year by Rock Health, a venture fund dedicated to digital health in San Francisco.

Celmatix is a personalized medicine company focused on fertility and women’s health based in New York, which the Fund first invested in in 2015 – a great example of the growing life sciences industry in the city.

Partnership Fund Investment Lodo Therapeutics Named in Top 10 Startups to Watch

Resource Type: Fund News, Partnership Fund

Chemical and Engineering News has named Fund investment, Lodo Therapeutics, one of its top 10 startups to watch.

Lodo Therapeutics takes an innovative approach to natural products drug discovery, using bacteria found in soil to uncover gene sequences that hold promising molecules to combat disease and infection. The Wall Street Journal recently wrote on the company’s use of New York City soil as a source of bacteria for their research, finding it to be as rich in microbes as soil found in the Amazon rain forest.

The Fund first invested in Lodo Therapeutics in 2015 as part of its life sciences portfolio, the company has also received funding from the Bill and Melinda Gates Foundation.

Kathryn Wylde and Winston Fisher on WCNY’s Capitol Pressroom

Resource Type: News

Kathryn Wylde, President and CEO at the Partnership for New York City, and Winston Fisher, a Partner at Fisher Brothers, appeared on WCNY’s Capitol Pressroom this morning to discuss their proposals for economic development in the city through the Regional Economic Development Council (REDC). They spoke about investments the REDC has made over the years through workforce development projects and community revitalization initiatives and the impact these have on areas in need of support.

Listen to the radio segment here:

See complete article on WCNY

Partnership Fund Investment Kasisto Announces Partnership with Mastercard

Resource Type: Fund News, Partnership Fund

At this week’s Money 20/20 conference, Mastercard announced a partnership with Kasisto to create a Mastercard bot for banks.

Kasisto is a graduate of the 2014 FinTech Innovation Lab and a Partnership Fund portfolio company.

The bot, Mastercard Kai, will use Kasisto’s Kai Banking on Messaging technology allowing customers a human-like conversation with their bank.

Learn more about the bot, currently in pilot phase, on the Kasisto website.

Accenture, Partnership Fund for New York City and Leading Banks Call for Applicants for New York FinTech Innovation Lab 2017

Resource Type: Fund News, Partnership Fund

Program helps leading financial technology entrepreneurs accelerate product and business development, and solidifies New York City’s position as the nation’s fintech capital

Applications are now being accepted for New York’s seventh annual FinTech Innovation Lab, a 12-week program co-founded by Accenture (NYSE: ACN) and the Partnership Fund for New York City that helps early- and growth-stage financial technology (fintech) companies accelerate product and business development by gaining exposure to top bank and venture capital executives. Applications are available at www.fintechinnovationlab.com and are due by December 1, 2016. An information session will be held for applicants on November 7. Read More

Partnership for New York City Announces 2016-2017 Class of David Rockefeller Fellows

Resource Type: News, Press Releases

 Annual Program Selects 23 Senior Executives Committed to Corporate Civic Engagement

NEW YORK, NY, October 14, 2016 – The Partnership for New York City, the city’s leading business organization, today announced the newest class of David Rockefeller Fellows, a group of twenty-three senior executives selected to participate in a year-long business and civic leadership program.

The 2016-2017 class of Fellows represents a cross-section of industries, including financial services, law, technology, retail and media. During the year, Fellows will have the opportunity to learn firsthand how New York City is run from top leaders in the private, public, and nonprofit sectors. Since its inception in 1989, 362 individuals have participated in the program. Read More

Statement from Kathryn Wylde, President & CEO of the Partnership for New York City, On Governor Cuomo’s Unveiling of New Pennsylvania Station Farley Complex

Resource Type: News, Statements

“Governor Cuomo is accelerating our major transportation projects and leveraging public partnerships to ensure that these projects are of the highest quality and that they’re delivered on time. Today’s announcement is great news for all New Yorkers, especially for the employers and commuters who will directly benefit from the new Penn-Farley Complex.”

CEO of EpiBone on CNBC

Resource Type: Fund News, News, Partnership Fund, Videos

Nina Tandon, CEO of EpiBone appeared on CNBC last week, discussing the company’s technology allowing patients to grow new bones in a lab to help heal from injury, illness or surgery.

The Partnership Fund invested in EpiBone through our BioAccelerate funding program—which provides early stage funding to NYC-based biotech companies spun out of local academic institutions. Located in Brooklyn, at the SUNY Downstate incubator and spun out of Columbia University, EpiBone is engineering stem cells into anatomically precise and patient-specific implants for skeletal reconstruction.